Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis

Medical Journal of Australia

Volumn 199, Issue 2, 2013, Pages 121-123

  Mohammadieh, Anna M ^a   Bowler, Simon D ^b   Silverstone, Elizabeth J ^a   Glanville, Allan R ^a   Yates, Deborah H ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS;

ABDOMINAL LYMPHANGIOLEIOMYOMA; ABDOMINAL TUMOR; ACNE; ACUTE APPENDICITIS; ADULT; ARTICLE; CHYLOUS ASCITES; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; INFLUENZA A; LYMPHANGIOLEIOMYOMATOSIS; LYMPHANGIOMYOMA; LYMPHOCYTOPENIA; MOUTH ULCER; MYALGIA; NAUSEA; OTALGIA; RECURRENT DISEASE; SCIATICA; SPORADIC LYMPHANGIOLEIOMYOMATOSIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VAGINA BLEEDING;

ABDOMINAL NEOPLASMS; ADULT; ANTINEOPLASTIC AGENTS; CHYLOUS ASCITES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 84880658045     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.11567     Document Type: Article

References (15)

1. Chorianopoulos D, Stratakos G. Lymphangioleiomyomatosis and tuberous sclerosis complex. Lung 2008; 186: 197-207.
2. Johnson SR, Cordier JF, Lazor R, et al; Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35: 14-26.
3. McCormack FX, Inoue Y, Moss J, et al; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-1606.
4. Sandrini A, Silverstone E, Yates DH. Menstrual cycle variation of retroperitoneal lymphangioleiomyomas in abdominal lymphangioleiomyomatosis. Intern Med J 2011; 41: 832-835.
5. Johnson SR, Whale CI, Hubbard RB, et al. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 2004; 59: 800-803.
6. Taillé C, Debray MP, Crestani B. Sirolimus treatment for pulmonary lymphangioleiomyomatosis. Ann Intern Med 2007; 146: 687-688.
7. Morton JM, McLean C, Booth SS, et al. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapaymcin treatment. J Heart Lung Transplant 2008; 27: 462-465.
8. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011; 154: 797-805.
9. Herry I, Neukirch C, Debray MP, et al. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 2007; 18: 76-77.
10. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151.
11. Piha-Paul SA, Hong DS, Kurzrock R. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus)- based treatment. J Clin Oncol 2011; 29: e333-e335.
12. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811.
13. Franz DN. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther 2011; 11: 1181-1192.
14. Avila NA, Kelly JA, Chu SC, et al. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology 2000; 216: 147-153.
15. Formica RN Jr, Lorber KM, Friedman AL, et al. The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004; 36 (2. Suppl): 495S-499S.